Innovation1 Biotech(OTC) IVBT

Market Cap$4.50K

Since IPO (2017)-100%

5 Year-100%

1 Year+0%

1 Month+0%

$0.00

+0.00%

+0.00Today

Innovation1 Biotech last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-07-24

Innovation1 Biotech stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-07-02
1 month	+0%	USD 0.00	2026-06-23
3 month	+0%	USD 0.00	2026-04-24
Year to date	+0%	USD 0.00	2025-12-29
1 year	+0%	USD 0.00	2025-07-22
3 year	-99.83%	USD 0.12	2023-07-25
5 year	-99.98%	USD 1.28	2021-07-23
Since inception	-100%	USD 292.60	2017-10-11

Innovation1 Biotech Financials at a Glance

Market Cap

$4.50K

Revenue (TTM)

$104.87K

Net Income (TTM)

-$5.30M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

1.18 (Average)

Dividend

$0.00

Beta (Volatility)

1.18 (Average)

Price

$0.00

Volume

Open

$0.00

Price

$0.00

Volume

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

Dividend

$0.00

Beta (Volatility)

1.18 (Average)

Price

$0.00

Volume

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

IVBT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Innovation1 Biotech

Innovation1 Biotech Inc. is a drug discovery enterprise focused on developing modified botanical Schedule 1 molecules for medical use in the United States. The company is advancing a pipeline of five proprietary prodrugs, each targeting specific medical conditions, including mental health and pediatric epilepsy.

Products and Services

Proprietary prodrugs for various medical conditions
Psychedelic compounds aimed at treating PTSD and depression
Cannabinoid-based treatments for pediatric epilepsy and inflammation

Growth Outlook

Pipeline includes five prodrugs in preclinical development
Focus on innovative treatments for mental health and addiction
Potential market expansion in the growing biotech sector

Financial Highlights

Recent quarterly net income of -$290,000
Trailing twelve months (TTM) revenue of $0
Cash and cash equivalents increased to $107,527 in Q2 2024

Innovation1 Biotech Inc. operates in the biotechnology sector, emphasizing innovative drug development. The company has a unique focus on modified botanical compounds, which positions it well within the expanding market for alternative therapies. Despite recent financial challenges, including a net income loss, the increase in cash reserves indicates potential for future operational stability. The ongoing development of its proprietary prodrugs may attract interest from investors looking for opportunities in the evolving healthcare landscape.

AI Generated • Aug 24, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Frederick E. Pierce, II

Website

www.innovation1bio.com

Headquarters

New York, NY 10016, US

IVBT Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

2074.16%

Return on Capital

N/A

Return on Assets

-7879.67%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.50K

Shares Outstanding

22.47M

Volume

Avg. Volume

0.444

Financials (TTM)

Gross Profit

$51.65K

Operating Income

-$308.28K

EBITDA

-$4.84M

Operating Cash Flow

-$515.40K

Capital Expenditure

-$5.00

Free Cash Flow

-$515.40K

Cash & ST Invst.

$107.53K

Total Debt

$605.06K

Innovation1 Biotech Performance Analysis

Innovation1 Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-08-31	USD 0	N/A
2023	2023-08-31	USD 0	N/A

Innovation1 Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2023-05-31	N/A
Q4	2023-08-31	N/A
Q1	2023-11-30	-100.0%
Q2	2024-02-29	N/A

Innovation1 Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-08-31	USD -2.73	N/A
2023	2023-08-31	USD -0.70	-74.5%

Innovation1 Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2023-05-31	92.5%
Q4	2023-08-31	-666.7%
Q1	2023-11-30	90.0%
Q2	2024-02-29	-1.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2024YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$261.00

+0.0%

Gross Margin

0.00%

N/A

Market Cap

$4.50K

N/A

Market Cap/Employee

$4.50K

N/A

Employees

N/A

Net Income

-$290.00K

+51.9%

EBITDA

-$149.74K

+73.5%

Quarterly Fundamentals

Name

Q2 2024YOY CHG

Total Cash

$107.53K

+104.9%

Total Debt

$605.06K

+1769.7%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$555.06K

+2382.2%

Short Term Debt

$50.00K

+400.0%

Return on Assets

-78.80%

N/A

Return on Invested Capital

42.57%

N/A

Free Cash Flow

-$148.29K

+29.0%

Operating Cash Flow

-$148.29K

+29.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

BXRXQBaudax Bio, Inc.

BXRXQBaudax Bio, Inc.$0.00+0.00%

KLDOKaleido Biosciences, Inc.

KLDOKaleido Biosciences, Inc.$0.00+0.00%

ARNIArno Therapeutics, Inc.

ARNIArno Therapeutics, Inc.$0.00+0.00%

XENOXeno Transplants Corporation

XENOXeno Transplants Corporation$0.00+0.00%

BTTXBetter Therapeutics, Inc.

BTTXBetter Therapeutics, Inc.$0.00+0.00%

TLOGTetraLogic Pharmaceuticals Corporation

TLOGTetraLogic Pharmaceuticals Corporation$0.00+0.00%

CALACalithera Biosciences, Inc.

CALACalithera Biosciences, Inc.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

KHCKraft Heinz

KHCKraft Heinz$24.60+0.01%

ACVAACV Auctions

ACVAACV Auctions$10.41+0.44%

TNONTenon Medical

TNONTenon Medical$5.93+0.12%

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF$19.16+0.03%

SMRNuScale Power

SMRNuScale Power$8.61-0.16%

NVDANvidia

NVDANvidia$218.29-0.00%

INTCIntel

INTCIntel$102.94+0.03%

Questions About IVBT

What is the current price of Innovation1 Biotech?

Innovation1 Biotech is trading at $0.00 per share.

What is the 52-week range for Innovation1 Biotech?

Over the past 52 weeks, Innovation1 Biotech has traded between $0.00 and $0.00.

How much debt does Innovation1 Biotech have?

As of the most recent reporting period, Innovation1 Biotech reported total debt of $229.00K.

How much cash does Innovation1 Biotech have on hand?

Innovation1 Biotech reported $49.85K in cash and cash equivalents in its most recent financial results.

What is Innovation1 Biotech’s dividend yield?

Innovation1 Biotech does not currently have a dividend yield.

Innovation1 Biotech(OTC) IVBT

Innovation1 Biotech Financials at a Glance

IVBT News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Innovation1 Biotech

IVBT Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Innovation1 Biotech Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About IVBT

What is the current price of Innovation1 Biotech?

What is the 52-week range for Innovation1 Biotech?

How much debt does Innovation1 Biotech have?

How much cash does Innovation1 Biotech have on hand?

What is Innovation1 Biotech’s dividend yield?

Premium Investing Services